TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7732981

Group type: EXPERIMENTAL
Intervention: 30 mg nicardipine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Open-label nicardipine (30 or 40 mg three times a day for 1 week)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 53
Study: 1975199

Group type: EXPERIMENTAL
Intervention: Atipamezole 100 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atipamezole 30 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atipamezole 10 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atipamezole (oral dosing)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study: 7298122

Group type: EXPERIMENTAL
Intervention: Family intervention program to modify the family diet toward a goal of 70 mEq sodium per person per day.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no dietary intervention).
Number of subjects: 80
Study: 31385637

Group type: EXPERIMENTAL
Intervention: Slice GRAPPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split-slice GRAPPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative acquisition with varied slice pairings
Number of subjects: 0
Study: 28052840

Group type: EXPERIMENTAL
Intervention: Web-based complaint-directed mini-interventions (CDMIs)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 329
Study: 25709097

Group type: EXPERIMENTAL
Intervention: Δ(9)‐THC 0.03 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Δ(9)‐THC 0.015 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24112372

Group type: EXPERIMENTAL
Intervention: Self-reported sleep disturbances
Number of subjects: 249
Study: 21406672

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitors plus nurse-delivered, telephone-based tailored patient education intervention (n=150)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitors plus Web-based tailored patient education intervention (n=150)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard care (n=150)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Both intervention groups (n=150 each)
Number of subjects: 450
Study: 19966651

Group type: EXPERIMENTAL
Intervention: 32-gauge needle
Number of subjects: 30

Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 30
Study: 17484218

Group type: EXPERIMENTAL
Intervention: Live pentavalent rotavirus vaccine (PRV)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1358
Study: 15754631

Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m2 daily for 5 days, repeated 5 times with 21-day intervals)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 35
Study: 11586196

Group type: EXPERIMENTAL
Intervention: Laparoscopic skills training (30 minutes daily for 10 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Laparoscopic skills training
Number of subjects: 12
Study: 9704732

Group type: EXPERIMENTAL
Intervention: VACOP-B for 12 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VACOP-B for 12 weeks plus high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: VACOP-B for 12 weeks plus HDT and ABMT
Number of subjects: 124
Study: 7988262

Group type: EXPERIMENTAL
Intervention: Preoperative mitomycin, vinblastine, and cisplatin (MVP) chemotherapy (cisplatin 120 mg/m2, mitomycin 8 mg/m2 on day 1 + 29, vinblastine 4.5 mg/m2 on days 1, 15, 22, and 29, and 2.0 mg/m2 on day 8)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Preoperative radiotherapy (44 Gy in 22 fractions to the primary tumor and mediastinum)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall toxicity
Number of subjects: 67
Study: 2498414

Group type: EXPERIMENTAL
Intervention: rt‐PA (recombinant tissue plasminogen activator)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 31923105

Group type: EXPERIMENTAL
Intervention: Active tACS (20 daily 40-min sessions at 77.5 Hz, 15 mA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham tACS (placebo control)
Number of subjects: 92
Study: 31634198

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir disoproxil fumarate (TDF) for pre‐exposure prophylaxis (PrEP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 28665071

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 34.5°C for 48 hours followed by 48 hours of slow rewarming
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 26231324

Group type: EXPERIMENTAL
Intervention: Financial incentives for lowering PO4
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Coaching about dietary and medication adherence
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 23057646

Group type: EXPERIMENTAL
Intervention: Extra care aide (CA) support
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Personal alarms (PA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study: 21529365

Group type: EXPERIMENTAL
Intervention: mRDT implementation in intervention health facilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control health facilities without mRDTs
Number of subjects: 0
Study: 20218321

Group type: EXPERIMENTAL
Intervention: Qianliean Suppository (1 pill per night for 28 days)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Yejuhua Suppository (1 pill per night for 28 days)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Qianliean Suppository
Number of subjects: 467

Group type: COMPARATOR
Intervention: Yejuhua Suppository
Number of subjects: 467
Study: 17020067

Group type: EXPERIMENTAL
Intervention: Ventilated nasal packs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ventilated (glove-finger) nasal packs
Number of subjects: 0
Study: 15190137

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 221
Study: 11679529

Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Salpingectomy in patients with ultrasound-visible hydrosalpinges
Number of subjects: 186

Group type: COMPARATOR
Intervention: No surgical intervention (control group)
Number of subjects: 186
Study: 10205311

Group type: EXPERIMENTAL
Intervention: Mixture of 50% medium‐chain triglycerides and 50% long-chain triglycerides
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100% long-chain triglycerides
Number of subjects: 20
Study: 7827351

Group type: EXPERIMENTAL
Intervention: Diabetic children
Number of subjects: 129
Study: 3124680

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT), 200 or 250 mg every 4 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Other regimens
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Monitoring antigenemia
Number of subjects: 16
Study: 29077181

Group type: EXPERIMENTAL
Intervention: Adjustable suture recession
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonadjustable suture recession
Number of subjects: 40
Study: 26999045

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated central venous catheters (CVCs)
Number of subjects: 8831

Group type: COMPARATOR
Intervention: Standard central venous catheters (CVCs)
Number of subjects: 8831
Study: 26226067

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 0
Study: 23442608

Group type: EXPERIMENTAL
Intervention: DTwP-Local
Number of subjects: 672

Group type: COMPARATOR
Intervention: DTwP-Pasteur
Number of subjects: 672
Study: 22162648

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wellness Education (WE)
Number of subjects: 14
Study: 17851757

Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg (TL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (L)
Number of subjects: 120
Study: 17146314

Group type: EXPERIMENTAL
Intervention: Energizers (classroom-based physical activity program)
Number of subjects: 243
Study: 12749480

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study: 10633513

Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide/60% oxygen inhalation
Number of subjects: 22

Group type: COMPARATOR
Intervention: 100% oxygen inhalation
Number of subjects: 22
Study: 8602667

Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(-1) edrophonium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study: 2368149

Group type: EXPERIMENTAL
Intervention: Double therapy (cyclosporine and steroids)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Triple therapy (cyclosporine in lower initial dose, azathioprine, and steroids)
Number of subjects: 209
Study: 99235

Group type: EXPERIMENTAL
Intervention: IV hyperalimentation (IVH) administered before and after the first course of CIA for a total of 31 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IV hyperalimentation (IVH)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CIA chemoimmunotherapy
Number of subjects: 26
Study: 30646862

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28464887

Group type: EXPERIMENTAL
Intervention: SBIRT Condition with face-to-face, tailored counseling focusing on child's illness, reducing child SHSe, caregiver smoking cessation, and nicotine replacement therapy option.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Habits Control Condition with face-to-face, tailored attention control '5-2-1-0' counseling focusing on improving child's health.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SBIRT Condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Habits Control Condition
Number of subjects: 0
Study: 26120056

Group type: EXPERIMENTAL
Intervention: Continuous morphine infusion (10 μg/kg/h)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 24930359

Group type: EXPERIMENTAL
Intervention: Varenicline (titrated up to 1 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21818622

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 50 U/Kg of rHuEPO
Number of subjects: 14
Study: 19254669

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation
Number of subjects: 0
Study: 17764013

Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract (BSE) 400 mg three times daily for 6 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract (BSE)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Open-label BSE therapy
Number of subjects: 31
Study: 15226088

Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha-tocopherol acetate, 400 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11794432

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Other antiarrhythmics
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study: 9818751

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g bd
Number of subjects: 400

Group type: COMPARATOR
Intervention: Imipenem‐cilastatin 1 g tds (50 mg/kg/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 400

Group type: COMPARATOR
Intervention: Imipenem‐cilastatin
Number of subjects: 400
Study: 8110569

Group type: EXPERIMENTAL
Intervention: 5% EMLA cream 2.5 g for 30 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5% EMLA cream 2.5 g for 60 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: amethocaine cream 1 g (5% w/w) for 30 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: amethocaine cream 1 g (5% w/w) for 60 min
Number of subjects: 120
Study: 3297679

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with 200 micrograms fentanyl (B:F 200 group)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with normal saline (B:F o group)
Number of subjects: 161
Study: 29643155

Group type: EXPERIMENTAL
Intervention: Immediate continuous femoral nerve block via catheter
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard analgesia (standard care)
Number of subjects: 118
Study: 27513363

Group type: EXPERIMENTAL
Intervention: Interactive program (n=46)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Psycho-educational self-help website (n=41)
Number of subjects: 87
Study: 26714758

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs) from birth (group A, n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Insecticide-treated bed nets (ITNs) from age 6 months (group B, n = 45)
Number of subjects: 90
Study: 23733232

Group type: EXPERIMENTAL
Intervention: Alphacypermethrin (ACYP) pour-on treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control group (C-group)
Number of subjects: 20
Study: 20066735

Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^7, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9
Number of subjects: 31
Study: 19363849

Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril-indapamide
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study: 19648155

Group type: COMPARATOR
Intervention: 0 ng ml(‐1) remifentanil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 ng ml(‐1) remifentanil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 ng ml(‐1) remifentanil
Number of subjects: 24
Study: 15811769

Group type: EXPERIMENTAL
Intervention: BCAA granules (n = 21, BCAA group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 43
Study: 11566624

Group type: EXPERIMENTAL
Intervention: TNF-alpha and NO donors in mitogen-activated, HIV-1-infected PBMC cultures
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: iNOS specific inhibitors
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neutralising anti-TNF-alpha monoclonal antibody
Number of subjects: 44

Group type: COMPARATOR
Intervention: Plasma TNF-alpha and NO levels in HIV-1-infected children
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HIV-1-infected children with higher viral load (> 4.7 log10)
Number of subjects: 44
Study: 9596400

Group type: EXPERIMENTAL
Intervention: EMG-triggered neuromuscular stimulation (EMG-stim)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no EMG-stim)
Number of subjects: 9
Study: 8181202

Group type: EXPERIMENTAL
Intervention: Cotinine (30 mg) intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3651943

Group type: EXPERIMENTAL
Intervention: One-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, containing 15 micrograms of hemagglutinin of each antigen)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Two-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, second dose administered 8 weeks after the first)
Number of subjects: 102
Study: 29931447

Group type: EXPERIMENTAL
Intervention: Weight-loss maintainers (≥10% weight loss maintained at 6 months)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Weight-loss regainers (did not maintain >10% weight loss at 6 months)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Diet adherence after the initial 11 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Weight loss at 15 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Weight-loss satisfaction from week 15 or 19
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 11-week dietary adherence and 15-week weight loss
Number of subjects: 58
Study: 30420123

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus lamivudine (300 mg)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Dolutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Two-drug regimen
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Three-drug regimen
Number of subjects: 1441
Study: 29990851

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg) based on total body weight (TBW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg) based on lean body weight (LBW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26116635

Group type: EXPERIMENTAL
Intervention: Physical therapy (kinesitherapy and electrotherapeutic procedures) including medicamentous therapy, walking exercises beyond the pain threshold, dynamic low‐burden kinesi exercises, interference therapy, diadynamic therapy, and electromagnetic field.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional non‐operative treatment including medicamentous therapy and walking exercises.
Number of subjects: 47
Study: 25144438

Group type: EXPERIMENTAL
Intervention: Partial-body cryotherapy (3 min at -110°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 12
Study: 22357724

Group type: COMPARATOR
Intervention: CMF+glu
Number of subjects: 30

Group type: COMPARATOR
Intervention: ePHF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 30
Study: 19593418

Group type: COMPARATOR
Intervention: No ankle brace (NB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lace-up brace (LU)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Semirigid brace (SR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stable group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Unstable group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All brace conditions
Number of subjects: 28
Study: 17488793

Group type: EXPERIMENTAL
Intervention: rhGH (0.46 mg/kg.wk) in daily sc injections
Number of subjects: 30

Group type: COMPARATOR
Intervention: No rhGH therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 30
Study: 15061962

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg, 2 mg/kg, and 3 mg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Etomidate (0.15 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inhalational anesthetics (enflurane, isoflurane, desflurane) at concentrations corresponding to 0 to 0.3, 0.5, 0.75, 1.0 and 1.5 MAC
Number of subjects: 150
Study: 11553254

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 34

Group type: COMPARATOR
Intervention: Laryngeal mask
Number of subjects: 34
Study: 9745140

Group type: EXPERIMENTAL
Intervention: Micanol monotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Micanol in combination with UVB phototherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo combined with UVB phototherapy
Number of subjects: 36
Study: 7700066

Group type: EXPERIMENTAL
Intervention: Inhibition of the angiotensin-converting enzyme
Number of subjects: 0
Study: 3191761

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol
Number of subjects: 28

Group type: COMPARATOR
Intervention: MDI with InspirEase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups (including MDI and nebulizer regimens)
Number of subjects: 28
Study: 29865075

Group type: EXPERIMENTAL
Intervention: Multi-domain intervention plus placebo
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: Isolated multi-domain intervention
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Number of subjects: 1293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1293
Study: 27419367

Group type: EXPERIMENTAL
Intervention: TETRA exposure during chest exposure in the first experiment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TETRA exposure during chest exposure in the second experiment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham exposure (control) in both experiments.
Number of subjects: 0
Study: 24061847

Group type: EXPERIMENTAL
Intervention: Tibialis anterior tendon transfer surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (casting only)
Number of subjects: 20
Study: 23319529

Group type: EXPERIMENTAL
Intervention: 3-hour web-based tobacco cessation education program (WeBREATHe)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Delayed training (control)
Number of subjects: 215
Study: 20127530

Group type: EXPERIMENTAL
Intervention: Central neuraxial blockade (anesthetic dose)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Central neuraxial blockade (analgesic dose)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Central neuraxial blockade (overall)
Number of subjects: 681
Study: 18716414

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg) and folic acid (10 mg/day) for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fluoxetine and placebo for 6 weeks
Number of subjects: 27
Study: 16631047

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime
Number of subjects: 13698

Group type: EXPERIMENTAL
Intervention: Perioperative levofloxacin eyedrops
Number of subjects: 13698

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 13698